Alzheimer’s

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

user April 6, 2023

ILAP Designation accelerates patient access and commercialization MIAMI, APRIL 5, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the...

MetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare Application

user October 26, 2022

Mission-Critical GPS SmartSole Allows Users to Track the Whereabouts of Loved Ones with Alzheimer’s and Autism Cambridge, UK, October 26th...

Treating Alzheimer’s: Is It Really an Autoimmune Disease?

user October 21, 2022

Although Alzheimer’s is still listed as an incurable neurodegenerative disease, medical science has come a long way in terms of...

Alzheimer’s

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

MetAlert, Inc. Selects Pod Group’s ENO ONE eSIM Solution to Connect “SmartSole” Healthcare Application

Treating Alzheimer’s: Is It Really an Autoimmune Disease?

FendX Engages Independent Trading Group (ITG), Inc. for Market Making Services and Engages Longtable Capital Partners for IR Services

NextGen Healthcare Supports Athletico Physical Therapy’s Growing Footprint

FDA Announces Formal Support for Voluntary Improvement Program (VIP)

Rho to Lead U.S. Clinical Trials for Next Generation of COVID-19 Vaccines as Part of $5 Billion NextGen Initiative

The Assistance Fund Opens New Program for Epidermolysis Bullosa

You may have missed